Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $158.48 in the prior trading day, Johnson & Johnson (NYSE: JNJ) closed at $159.09, up 0.38%. In other words, the price has increased by $0.38 from its previous closing price. On the day, 7.14 million shares were traded. JNJ stock price reached its highest trading level at $159.495 during the session, while it also had its lowest trading level at $157.85.
Ratios:
Our goal is to gain a better understanding of JNJ by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.03 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.86. For the most recent quarter (mrq), Quick Ratio is recorded 0.85 and its Current Ratio is at 1.07. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.44.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Daiwa Securities on July 23, 2024, Downgraded its rating to Neutral and sets its target price to $150 from $160 previously.
HSBC Securities Upgraded its Hold to Buy on April 18, 2024, while the target price for the stock was maintained at $170.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 13 ’24 when Broadhurst Vanessa sold 8,891 shares for $162.16 per share. The transaction valued at 1,441,765 led to the insider holds 15,043 shares of the business.
JOHNSON & JOHNSON sold 3,725 shares of JNJ for $96,142 on Feb 16 ’24. The 10% Owner now owns 4,099,575 shares after completing the transaction at $25.81 per share. On Feb 09 ’24, another insider, Taubert Jennifer L, who serves as the EVP, WW Chair, Pharmaceuticals of the company, sold 59,397 shares for $156.27 each. As a result, the insider received 9,281,969 and left with 141,416 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JNJ now has a Market Capitalization of 382967808000 and an Enterprise Value of 397515980800. As of this moment, Johnson’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.00, and their Forward P/E ratio for the next fiscal year is 14.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.16. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.42 while its Price-to-Book (P/B) ratio in mrq is 5.35. Its current Enterprise Value per Revenue stands at 4.592 whereas that against EBITDA is 12.808.
Stock Price History:
Over the past 52 weeks, JNJ has reached a high of $175.39, while it has fallen to a 52-week low of $143.13. The 50-Day Moving Average of the stock is 4.71%, while the 200-Day Moving Average is calculated to be 3.46%.
Shares Statistics:
The stock has traded on average 7.29M shares per day over the past 3-months and 7625810 shares per day over the last 10 days, according to various share statistics. A total of 2.41B shares are outstanding, with a floating share count of 2.40B. Insiders hold about 0.16% of the company’s shares, while institutions hold 73.32% stake in the company. Shares short for JNJ as of 1722384000 were 18848671 with a Short Ratio of 2.59, compared to 1719532800 on 21174103. Therefore, it implies a Short% of Shares Outstanding of 18848671 and a Short% of Float of 0.7799999999999999.
Dividends & Splits
In the trailing 12 months, JNJ’s forward annual dividend rate was 4.81, compared to 4.81 this year. Against a Trailing Annual Dividend Yield of 0.030350834The stock’s 5-year Average Dividend Yield is 2.71.
Earnings Estimates
Johnson & Johnson (JNJ) is presently subject to a detailed evaluation by 14.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $2.3, with high estimates of $2.51 and low estimates of $1.94.
Analysts are recommending an EPS of between $10.11 and $9.97 for the fiscal current year, implying an average EPS of $10.03. EPS for the following year is $10.71, with 20.0 analysts recommending between $11.54 and $10.16.
Revenue Estimates
13 analysts predict $22.12B in revenue for the current quarter. It ranges from a high estimate of $22.32B to a low estimate of $21.89B. As of the current estimate, Johnson & Johnson’s year-ago sales were $21.03BFor the next quarter, 13 analysts are estimating revenue of $22.46B. There is a high estimate of $22.77B for the next quarter, whereas the lowest estimate is $22.13B.
A total of 19 analysts have provided revenue estimates for JNJ’s current fiscal year. The highest revenue estimate was $89.04B, while the lowest revenue estimate was $84B, resulting in an average revenue estimate of $88.25B. In the same quarter a year ago, actual revenue was $85.16BBased on 19 analysts’ estimates, the company’s revenue will be $91.11B in the next fiscal year. The high estimate is $92.11B and the low estimate is $90.34B.
